The estimated Net Worth of Herschell Sklaroff is at least $163 Thousand dollars as of 5 December 2006. Herschell Sklaroff owns over 37,008 units of Icad Inc stock worth over $9,638 and over the last 20 years Herschell sold ICAD stock worth over $153,161.
Sign up
Herschell Sklaroff ICAD stock SEC Form 4 insiders trading
Herschell has made over 3 trades of the Icad Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Herschell sold 37,008 units of ICAD stock worth $123,237 on 5 December 2006.
The largest trade Herschell's ever made was selling 37,008 units of Icad Inc stock on 5 December 2006 worth over $123,237. On average, Herschell trades about 6,517 units every 122 days since 2004. As of 5 December 2006 Herschell still owns at least 6,934 units of Icad Inc stock.
You can see the complete history of Herschell Sklaroff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Herschell Sklaroff's mailing address?
Herschell's mailing address filed with the SEC is 1185 PARK AVENUE, APT 7D, , NEW YORK, NY, 10128.
Insiders trading at Icad Inc
Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton, and Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.
What does Icad Inc do?
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
What does Icad Inc's logo look like?
Complete history of Herschell Sklaroff stock trades at Icad Inc
Icad Inc executives and stock owners
Icad Inc executives and other stock owners filed with the SEC include:
-
Michael S. Klein,
Exec. Chairman & CEO -
Stacey Stevens,
President -
Jonathan Go,
Chief Technology Officer -
Michael Klein,
Executive Chairman of the Board, Chief Executive Officer -
Stacey M. Stevens,
Pres -
Jonathan Go,
Chief Technology Officer -
Andrew Sassine,
Independent Director -
Susan Wood,
Independent Director -
Rakesh Patel,
Independent Director -
Jeremy Feffer,
Investor Relations Contact Officer -
Nathaniel Dalton,
Independent Director -
R. Scott Areglado,
Chief Financial Officer -
Jeffrey Sirek,
Chief Commercial Officer -
Brian Testa,
Chief People Officer -
Annette L. Heroux,
VP of Admin. -
Charles Ross Carter,
CFO & Sec. -
Rachel Brem,
Director -
Steven N Rappaport,
Director -
Robert L Goodman,
Director -
Dr Lawrence Howard,
Director -
Anthony F Ecock,
Director -
Timothy Norris Irish,
Director -
Richard Christopher,
Executive VP and CFO -
Andy Sassine,
Director -
Somu Subramaniam,
Director -
Elliot J Md Mba Sussman,
Director -
Kenneth M Ferry,
President, CEO -
James Harlan,
Director -
George P Farley,
Director -
W Scott Parr,
Chief Executive Officer, Presi -
Herschell Sklaroff,
Director -
John De Biase,
Vice President of Sales -
Annette Heroux,
Chief Financial Officer -
Steven K Rogers,
Chief Scientific Officer -
Peter Farrell,
EVP Marketing -
Thomas E Shoup,
VP, Staff Operations -
James L Corbett,
Chief Commercial Officer -
Kevin Woods,
Vice President, Research & Dev -
Samuel Ronci,
Vice President of Operations -
Robert Howard,
Director -
Kevin C Burns,
Executive VP of Finance, CFO -
Darlene M Deptula Hicks,
Executive VP of Finance, CFO -
Maha Sallam,
Executive Vice President -
Jeffrey H Barnes,
Executive VP of Sales -
Dana R Brown,
See Remarks -
Charles Ross Carter,
CHIEF FINANCIAL OFFICER -
Hedvig Hricak,
Director -
Daniel Joseph Shea,
See Remarks -
Eric Lonnqvist,
See Remarks -
Michael John Doyle,
Director